| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 219 | 2024 | 11206 | 7.750 |
Why?
|
| Prostate | 62 | 2024 | 1781 | 3.530 |
Why?
|
| PTEN Phosphohydrolase | 33 | 2024 | 1119 | 2.470 |
Why?
|
| Receptors, Androgen | 30 | 2024 | 1084 | 2.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 93 | 2024 | 8635 | 2.120 |
Why?
|
| Lipogenesis | 7 | 2020 | 216 | 1.740 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 14 | 2024 | 81 | 1.500 |
Why?
|
| Proto-Oncogene Proteins c-myc | 11 | 2024 | 998 | 1.460 |
Why?
|
| Tumor Suppressor Proteins | 32 | 2015 | 2819 | 1.430 |
Why?
|
| Cell Cycle Proteins | 28 | 2024 | 3463 | 1.430 |
Why?
|
| AMP-Activated Protein Kinases | 8 | 2015 | 598 | 1.260 |
Why?
|
| Adenocarcinoma | 45 | 2022 | 6400 | 1.250 |
Why?
|
| Endopeptidases | 7 | 2013 | 772 | 1.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 28 | 2024 | 319 | 1.120 |
Why?
|
| Genes, Tumor Suppressor | 22 | 2018 | 1064 | 1.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 17 | 2024 | 2884 | 1.080 |
Why?
|
| Gene Expression Profiling | 46 | 2023 | 9507 | 1.080 |
Why?
|
| Cell Transformation, Neoplastic | 29 | 2022 | 2847 | 1.080 |
Why?
|
| Metabolomics | 5 | 2021 | 1675 | 1.010 |
Why?
|
| Immunohistochemistry | 88 | 2021 | 11138 | 0.940 |
Why?
|
| Epithelial Cells | 25 | 2022 | 3697 | 0.930 |
Why?
|
| Cell Line, Tumor | 70 | 2024 | 17149 | 0.910 |
Why?
|
| Male | 326 | 2024 | 364781 | 0.900 |
Why?
|
| Prostatectomy | 24 | 2024 | 1840 | 0.860 |
Why?
|
| RNA, Neoplasm | 13 | 2017 | 751 | 0.830 |
Why?
|
| Androgens | 17 | 2024 | 1285 | 0.780 |
Why?
|
| Trans-Activators | 17 | 2016 | 2858 | 0.780 |
Why?
|
| Humans | 438 | 2024 | 768451 | 0.760 |
Why?
|
| Oncogene Proteins, Fusion | 17 | 2024 | 1614 | 0.760 |
Why?
|
| Periodicals as Topic | 8 | 2022 | 1468 | 0.760 |
Why?
|
| Microtubule-Associated Proteins | 11 | 2001 | 1078 | 0.750 |
Why?
|
| Tumor Suppressor Protein p53 | 23 | 2023 | 2964 | 0.750 |
Why?
|
| RNA, Messenger | 38 | 2021 | 12813 | 0.750 |
Why?
|
| Signal Transduction | 37 | 2024 | 23638 | 0.730 |
Why?
|
| Neoplasm Proteins | 23 | 2020 | 3611 | 0.730 |
Why?
|
| N-Acetylglucosaminyltransferases | 4 | 2024 | 167 | 0.720 |
Why?
|
| Oncogenes | 11 | 2021 | 1235 | 0.710 |
Why?
|
| CpG Islands | 15 | 2008 | 1209 | 0.700 |
Why?
|
| Cyclin-Dependent Kinases | 14 | 2024 | 664 | 0.700 |
Why?
|
| In Situ Hybridization | 18 | 2015 | 1906 | 0.700 |
Why?
|
| Stromal Cells | 4 | 2024 | 1335 | 0.690 |
Why?
|
| Cell Proliferation | 32 | 2024 | 10494 | 0.670 |
Why?
|
| Tissue Array Analysis | 16 | 2021 | 551 | 0.640 |
Why?
|
| Barrett Esophagus | 8 | 2015 | 494 | 0.630 |
Why?
|
| beta Catenin | 7 | 2023 | 1048 | 0.610 |
Why?
|
| Prostate-Specific Antigen | 20 | 2023 | 2483 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-akt | 17 | 2022 | 2465 | 0.560 |
Why?
|
| Mice | 94 | 2024 | 82045 | 0.560 |
Why?
|
| Colorectal Neoplasms | 29 | 2021 | 6978 | 0.560 |
Why?
|
| Neoplasms | 28 | 2021 | 22386 | 0.550 |
Why?
|
| Phosphoprotein Phosphatases | 6 | 1998 | 329 | 0.550 |
Why?
|
| Enzyme Activators | 2 | 2014 | 57 | 0.540 |
Why?
|
| Cell Lineage | 6 | 2019 | 2575 | 0.530 |
Why?
|
| Apoptosis | 22 | 2022 | 9526 | 0.520 |
Why?
|
| Gene Expression Regulation, Enzymologic | 10 | 2021 | 1170 | 0.520 |
Why?
|
| Paraffin Embedding | 7 | 2020 | 306 | 0.520 |
Why?
|
| Androgen Antagonists | 10 | 2024 | 1418 | 0.520 |
Why?
|
| Neoplasm Metastasis | 29 | 2020 | 4931 | 0.500 |
Why?
|
| Serine Endopeptidases | 9 | 2024 | 1032 | 0.500 |
Why?
|
| Animals | 123 | 2024 | 169418 | 0.490 |
Why?
|
| Histone Demethylases | 1 | 2018 | 322 | 0.490 |
Why?
|
| Mass Spectrometry | 5 | 2019 | 2204 | 0.480 |
Why?
|
| Protein Tyrosine Phosphatases | 7 | 2007 | 458 | 0.480 |
Why?
|
| Polymerase Chain Reaction | 27 | 2014 | 6091 | 0.470 |
Why?
|
| Enzyme Inhibitors | 11 | 2020 | 3734 | 0.470 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2019 | 125 | 0.470 |
Why?
|
| Microsatellite Instability | 10 | 2010 | 726 | 0.470 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 19 | 2020 | 4586 | 0.460 |
Why?
|
| Tumor Microenvironment | 10 | 2024 | 3939 | 0.460 |
Why?
|
| Disease Progression | 37 | 2024 | 13655 | 0.440 |
Why?
|
| cdc25 Phosphatases | 4 | 2003 | 60 | 0.440 |
Why?
|
| Phosphoproteins | 7 | 2008 | 2450 | 0.430 |
Why?
|
| Stem Cells | 5 | 2020 | 3538 | 0.430 |
Why?
|
| Cell Division | 15 | 2014 | 4479 | 0.430 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2024 | 1671 | 0.420 |
Why?
|
| Mitogen-Activated Protein Kinases | 5 | 1998 | 1246 | 0.420 |
Why?
|
| Lipid Metabolism | 5 | 2024 | 1898 | 0.410 |
Why?
|
| Epigenomics | 1 | 2018 | 956 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2022 | 9425 | 0.410 |
Why?
|
| Carcinoma | 13 | 2015 | 2341 | 0.410 |
Why?
|
| Antineoplastic Agents | 18 | 2019 | 13708 | 0.410 |
Why?
|
| Tumor Cells, Cultured | 26 | 2021 | 6135 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2019 | 5342 | 0.400 |
Why?
|
| Aged | 115 | 2024 | 171520 | 0.400 |
Why?
|
| Esophageal Neoplasms | 6 | 2015 | 1676 | 0.400 |
Why?
|
| Cysteine Endopeptidases | 5 | 2004 | 551 | 0.400 |
Why?
|
| Neoplasm Invasiveness | 18 | 2020 | 3637 | 0.390 |
Why?
|
| DNA-Binding Proteins | 22 | 2024 | 9623 | 0.390 |
Why?
|
| Gene Amplification | 13 | 2017 | 1091 | 0.390 |
Why?
|
| Quantum Dots | 3 | 2009 | 167 | 0.380 |
Why?
|
| Multienzyme Complexes | 5 | 2004 | 666 | 0.380 |
Why?
|
| Genes, myc | 8 | 2022 | 391 | 0.380 |
Why?
|
| Prognosis | 54 | 2021 | 30028 | 0.370 |
Why?
|
| Cyclin-Dependent Kinase 9 | 2 | 2021 | 68 | 0.360 |
Why?
|
| Colonic Neoplasms | 12 | 2009 | 2544 | 0.360 |
Why?
|
| Immediate-Early Proteins | 4 | 1998 | 444 | 0.360 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2015 | 798 | 0.360 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 2659 | 0.360 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 3116 | 0.360 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2015 | 2254 | 0.360 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 3240 | 0.360 |
Why?
|
| Middle Aged | 120 | 2024 | 223418 | 0.350 |
Why?
|
| Ubiquitin Thiolesterase | 8 | 2013 | 467 | 0.350 |
Why?
|
| Retinoblastoma Protein | 7 | 2021 | 673 | 0.350 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 5 | 1998 | 492 | 0.350 |
Why?
|
| Cytoplasm | 6 | 2012 | 1503 | 0.340 |
Why?
|
| Genes, ras | 12 | 2010 | 666 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2012 | 568 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2021 | 5709 | 0.330 |
Why?
|
| S-Phase Kinase-Associated Proteins | 2 | 2009 | 89 | 0.330 |
Why?
|
| Oncogene Proteins | 6 | 2013 | 718 | 0.330 |
Why?
|
| Down-Regulation | 8 | 2014 | 2944 | 0.330 |
Why?
|
| Genes, p53 | 9 | 2006 | 716 | 0.330 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2015 | 410 | 0.330 |
Why?
|
| Immunoenzyme Techniques | 13 | 2009 | 1706 | 0.330 |
Why?
|
| RNA, Small Interfering | 11 | 2021 | 3437 | 0.320 |
Why?
|
| MicroRNAs | 7 | 2023 | 3805 | 0.320 |
Why?
|
| Neoplasm Transplantation | 16 | 2021 | 2017 | 0.320 |
Why?
|
| Neoplasm Staging | 34 | 2022 | 11249 | 0.320 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2011 | 208 | 0.320 |
Why?
|
| Fatty Acids | 2 | 2014 | 1818 | 0.320 |
Why?
|
| Palmitic Acid | 2 | 2008 | 149 | 0.310 |
Why?
|
| DNA Methylation | 21 | 2014 | 4421 | 0.310 |
Why?
|
| Anticarcinogenic Agents | 2 | 2014 | 251 | 0.310 |
Why?
|
| Cell Cycle | 13 | 2013 | 2942 | 0.310 |
Why?
|
| Receptor, erbB-2 | 9 | 2015 | 2586 | 0.310 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 16 | 2017 | 3794 | 0.310 |
Why?
|
| In Situ Hybridization, Fluorescence | 15 | 2017 | 2525 | 0.310 |
Why?
|
| Wnt1 Protein | 1 | 2008 | 123 | 0.310 |
Why?
|
| Pathology, Molecular | 1 | 2011 | 329 | 0.310 |
Why?
|
| Cell Movement | 11 | 2021 | 5223 | 0.300 |
Why?
|
| Research Design | 2 | 2021 | 6217 | 0.300 |
Why?
|
| Nuclear Proteins | 17 | 2024 | 5808 | 0.300 |
Why?
|
| Transcription Factors | 17 | 2023 | 12174 | 0.300 |
Why?
|
| Prostatitis | 2 | 2019 | 102 | 0.300 |
Why?
|
| Proto-Oncogene Proteins | 18 | 2009 | 4534 | 0.300 |
Why?
|
| Transcription, Genetic | 11 | 2017 | 7599 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2022 | 11843 | 0.300 |
Why?
|
| Endocytosis | 1 | 2012 | 960 | 0.290 |
Why?
|
| Mutation | 42 | 2023 | 30243 | 0.290 |
Why?
|
| DNA, Neoplasm | 18 | 2009 | 1749 | 0.290 |
Why?
|
| Tissue Fixation | 4 | 2017 | 245 | 0.290 |
Why?
|
| Enzyme Activation | 12 | 2021 | 3594 | 0.290 |
Why?
|
| Mice, Transgenic | 22 | 2021 | 9558 | 0.290 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2000 | 354 | 0.280 |
Why?
|
| Lymphatic Metastasis | 14 | 2018 | 2930 | 0.280 |
Why?
|
| Neuroendocrine Tumors | 4 | 2020 | 649 | 0.280 |
Why?
|
| Carbon-Nitrogen Lyases | 1 | 2006 | 8 | 0.280 |
Why?
|
| Urologic Neoplasms | 3 | 2015 | 319 | 0.270 |
Why?
|
| Ki-67 Antigen | 12 | 2015 | 631 | 0.270 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 4 | 2000 | 326 | 0.270 |
Why?
|
| Cell Differentiation | 16 | 2024 | 11674 | 0.270 |
Why?
|
| Blotting, Western | 17 | 2011 | 5042 | 0.270 |
Why?
|
| Metformin | 3 | 2023 | 914 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 3 | 2006 | 1357 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 7 | 2014 | 2882 | 0.270 |
Why?
|
| Microfilament Proteins | 2 | 2003 | 1136 | 0.260 |
Why?
|
| Muscle Proteins | 2 | 2003 | 1165 | 0.260 |
Why?
|
| Acetyl-CoA Carboxylase | 2 | 2018 | 72 | 0.260 |
Why?
|
| Lung Neoplasms | 18 | 2020 | 13589 | 0.260 |
Why?
|
| Breast Neoplasms | 20 | 2016 | 21156 | 0.260 |
Why?
|
| Prospective Studies | 44 | 2024 | 54914 | 0.250 |
Why?
|
| Membrane Proteins | 9 | 2021 | 7895 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 4 | 2012 | 369 | 0.250 |
Why?
|
| Medical Oncology | 2 | 2019 | 2347 | 0.250 |
Why?
|
| Precancerous Conditions | 6 | 2011 | 988 | 0.240 |
Why?
|
| Gene Silencing | 9 | 2014 | 1503 | 0.240 |
Why?
|
| Lymphoma, B-Cell | 2 | 2003 | 945 | 0.240 |
Why?
|
| Follow-Up Studies | 29 | 2024 | 39430 | 0.240 |
Why?
|
| RNA Splicing | 2 | 2021 | 906 | 0.240 |
Why?
|
| DNA Copy Number Variations | 5 | 2015 | 2046 | 0.240 |
Why?
|
| Gene Dosage | 7 | 2017 | 1221 | 0.240 |
Why?
|
| Dihydrotestosterone | 3 | 2018 | 195 | 0.230 |
Why?
|
| Response Elements | 2 | 2024 | 308 | 0.230 |
Why?
|
| Academies and Institutes | 2 | 2020 | 326 | 0.230 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 3 | 2000 | 40 | 0.230 |
Why?
|
| Fluorescent Antibody Technique | 6 | 2020 | 2477 | 0.230 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2009 | 617 | 0.230 |
Why?
|
| Mice, Nude | 12 | 2013 | 3635 | 0.230 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2021 | 614 | 0.230 |
Why?
|
| Microsatellite Repeats | 10 | 2006 | 784 | 0.230 |
Why?
|
| Smad4 Protein | 3 | 2015 | 193 | 0.230 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2000 | 111 | 0.220 |
Why?
|
| Receptors, Adiponectin | 2 | 2015 | 82 | 0.220 |
Why?
|
| Homeodomain Proteins | 8 | 2023 | 2430 | 0.220 |
Why?
|
| Aneuploidy | 3 | 2024 | 572 | 0.220 |
Why?
|
| ras GTPase-Activating Proteins | 2 | 2016 | 95 | 0.220 |
Why?
|
| Skin Neoplasms | 5 | 2018 | 5891 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 8 | 2022 | 2067 | 0.210 |
Why?
|
| Adult | 72 | 2024 | 223542 | 0.210 |
Why?
|
| Proto-Oncogene Proteins B-raf | 14 | 2011 | 2072 | 0.210 |
Why?
|
| Phosphorylation | 16 | 2021 | 8332 | 0.210 |
Why?
|
| DNA Mutational Analysis | 9 | 2015 | 4120 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2017 | 5426 | 0.210 |
Why?
|
| Melanoma | 6 | 2018 | 5740 | 0.210 |
Why?
|
| Tankyrases | 1 | 2022 | 14 | 0.200 |
Why?
|
| Aged, 80 and over | 40 | 2021 | 59680 | 0.200 |
Why?
|
| Up-Regulation | 11 | 2022 | 4138 | 0.200 |
Why?
|
| Carcinoma, Small Cell | 4 | 2019 | 420 | 0.200 |
Why?
|
| Carcinoma, Embryonal | 2 | 2003 | 36 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2017 | 16029 | 0.200 |
Why?
|
| Stathmin | 2 | 2020 | 70 | 0.200 |
Why?
|
| Prostatic Diseases | 2 | 2006 | 57 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 7 | 2018 | 2896 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2009 | 934 | 0.200 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2016 | 708 | 0.200 |
Why?
|
| Carotenoids | 2 | 2016 | 621 | 0.190 |
Why?
|
| Flavonoids | 1 | 2005 | 447 | 0.190 |
Why?
|
| Ubiquitin | 2 | 2006 | 843 | 0.190 |
Why?
|
| Proto-Oncogenes | 2 | 2010 | 323 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2014 | 287 | 0.190 |
Why?
|
| Atrophy | 4 | 2019 | 1648 | 0.190 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2001 | 69 | 0.190 |
Why?
|
| Cell Death | 2 | 2024 | 1684 | 0.190 |
Why?
|
| Mice, Knockout | 12 | 2021 | 14480 | 0.180 |
Why?
|
| BRCA1 Protein | 3 | 2020 | 1158 | 0.180 |
Why?
|
| Carrier Proteins | 10 | 2016 | 4948 | 0.180 |
Why?
|
| Seminoma | 2 | 2003 | 136 | 0.180 |
Why?
|
| Chromatin | 4 | 2023 | 2969 | 0.180 |
Why?
|
| Taxoids | 3 | 2014 | 669 | 0.180 |
Why?
|
| Cyclin D1 | 3 | 2015 | 454 | 0.180 |
Why?
|
| Cell Growth Processes | 3 | 2013 | 383 | 0.180 |
Why?
|
| Neoplasms, Bone Tissue | 1 | 2020 | 7 | 0.180 |
Why?
|
| Interferons | 2 | 2021 | 714 | 0.180 |
Why?
|
| Gene Rearrangement | 4 | 2015 | 1139 | 0.180 |
Why?
|
| Isoenzymes | 2 | 2021 | 1685 | 0.180 |
Why?
|
| Monosaccharide Transport Proteins | 2 | 2000 | 437 | 0.180 |
Why?
|
| Activins | 1 | 2022 | 211 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 9 | 2022 | 1766 | 0.180 |
Why?
|
| Bone Neoplasms | 6 | 2015 | 2562 | 0.170 |
Why?
|
| Mammary Glands, Human | 2 | 2016 | 202 | 0.170 |
Why?
|
| Metabolome | 2 | 2019 | 1009 | 0.170 |
Why?
|
| Neuroectodermal Tumors | 1 | 2000 | 23 | 0.170 |
Why?
|
| G1 Phase | 3 | 2014 | 404 | 0.170 |
Why?
|
| Survival Rate | 17 | 2020 | 12875 | 0.170 |
Why?
|
| Female | 99 | 2022 | 396943 | 0.170 |
Why?
|
| DNA Damage | 4 | 2024 | 2461 | 0.170 |
Why?
|
| Transfection | 11 | 2012 | 5767 | 0.170 |
Why?
|
| Cyclic AMP Response Element-Binding Protein A | 1 | 2019 | 21 | 0.170 |
Why?
|
| Gene Expression | 15 | 2017 | 7605 | 0.170 |
Why?
|
| Quality Improvement | 1 | 2015 | 3858 | 0.170 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1999 | 91 | 0.170 |
Why?
|
| Antioxidants | 3 | 2017 | 1678 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 6 | 2015 | 712 | 0.170 |
Why?
|
| Coffee | 1 | 2024 | 598 | 0.170 |
Why?
|
| DNA Fragmentation | 2 | 2012 | 240 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 6 | 2016 | 2643 | 0.170 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2014 | 797 | 0.170 |
Why?
|
| Hematologic Tests | 1 | 2020 | 240 | 0.170 |
Why?
|
| Glycolysis | 1 | 2004 | 838 | 0.170 |
Why?
|
| Prostatic Hyperplasia | 5 | 2014 | 523 | 0.170 |
Why?
|
| DNA Primers | 7 | 2008 | 2826 | 0.170 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2018 | 1943 | 0.170 |
Why?
|
| Multigene Family | 6 | 2010 | 1081 | 0.170 |
Why?
|
| Octreotide | 1 | 2020 | 155 | 0.160 |
Why?
|
| NF-kappa B | 4 | 2023 | 2491 | 0.160 |
Why?
|
| Liposarcoma | 2 | 2014 | 289 | 0.160 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2020 | 188 | 0.160 |
Why?
|
| Receptors, Somatomedin | 1 | 2018 | 57 | 0.160 |
Why?
|
| Esophagus | 2 | 2004 | 1045 | 0.160 |
Why?
|
| Immunoblotting | 5 | 2015 | 1650 | 0.160 |
Why?
|
| Obesity | 7 | 2024 | 13065 | 0.160 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2020 | 270 | 0.160 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2015 | 252 | 0.160 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2021 | 333 | 0.160 |
Why?
|
| Genes, Immunoglobulin | 1 | 1999 | 286 | 0.160 |
Why?
|
| Lactic Acid | 1 | 2024 | 1140 | 0.160 |
Why?
|
| Lymphocytosis | 1 | 1999 | 121 | 0.160 |
Why?
|
| Proteasome Endopeptidase Complex | 6 | 2011 | 1322 | 0.160 |
Why?
|
| Piperidines | 2 | 2020 | 1664 | 0.160 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 170 | 0.150 |
Why?
|
| Testicular Neoplasms | 2 | 2003 | 806 | 0.150 |
Why?
|
| Serologic Tests | 1 | 2020 | 383 | 0.150 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2020 | 279 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2008 | 2434 | 0.150 |
Why?
|
| Orchiectomy | 4 | 2013 | 466 | 0.150 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 102 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2019 | 18048 | 0.150 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 749 | 0.150 |
Why?
|
| Base Sequence | 15 | 2014 | 12428 | 0.150 |
Why?
|
| Loss of Heterozygosity | 7 | 2007 | 663 | 0.150 |
Why?
|
| Stress, Physiological | 2 | 2015 | 1409 | 0.150 |
Why?
|
| Cohort Studies | 24 | 2020 | 41797 | 0.150 |
Why?
|
| Ovarian Neoplasms | 6 | 2015 | 4906 | 0.150 |
Why?
|
| Body Mass Index | 6 | 2017 | 13030 | 0.140 |
Why?
|
| Dual Specificity Phosphatase 1 | 4 | 1998 | 43 | 0.140 |
Why?
|
| Testosterone | 5 | 2017 | 2493 | 0.140 |
Why?
|
| Neutrophils | 2 | 2020 | 3790 | 0.140 |
Why?
|
| Caveolin 1 | 3 | 2008 | 255 | 0.140 |
Why?
|
| Androstenes | 2 | 2019 | 186 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 342 | 0.140 |
Why?
|
| Cell Nucleus | 9 | 2012 | 2889 | 0.140 |
Why?
|
| Patient Selection | 2 | 2009 | 4266 | 0.140 |
Why?
|
| Formaldehyde | 3 | 2015 | 361 | 0.140 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2017 | 71 | 0.140 |
Why?
|
| Intestinal Neoplasms | 1 | 1999 | 317 | 0.140 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2014 | 474 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2006 | 595 | 0.140 |
Why?
|
| HeLa Cells | 2 | 2014 | 3090 | 0.140 |
Why?
|
| Mice, SCID | 5 | 2021 | 2633 | 0.140 |
Why?
|
| Protein Kinase C | 1 | 2021 | 1207 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2023 | 3520 | 0.140 |
Why?
|
| Genes, cdc | 1 | 1997 | 114 | 0.140 |
Why?
|
| Receptors, Estrogen | 4 | 2002 | 2243 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 2 | 2020 | 940 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 649 | 0.140 |
Why?
|
| Protein Phosphatase 1 | 4 | 1998 | 135 | 0.140 |
Why?
|
| Organic Anion Transporters | 1 | 2017 | 101 | 0.130 |
Why?
|
| Brain Neoplasms | 3 | 2010 | 9182 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 4 | 2007 | 1615 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 5 | 1998 | 474 | 0.130 |
Why?
|
| Medulloblastoma | 4 | 2000 | 682 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2018 | 1905 | 0.130 |
Why?
|
| Biopsy | 8 | 2023 | 6816 | 0.130 |
Why?
|
| Osteopontin | 2 | 2015 | 307 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2010 | 277 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 3 | 2015 | 165 | 0.130 |
Why?
|
| Epithelium | 2 | 2017 | 1610 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3619 | 0.130 |
Why?
|
| Rectal Neoplasms | 4 | 2003 | 1179 | 0.130 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2018 | 554 | 0.130 |
Why?
|
| Prednisone | 2 | 2017 | 1568 | 0.130 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 98 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2018 | 384 | 0.130 |
Why?
|
| Nonsteroidal Anti-Androgens | 1 | 2015 | 9 | 0.120 |
Why?
|
| Lipids | 2 | 2024 | 3346 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2014 | 958 | 0.120 |
Why?
|
| Genes, Homeobox | 3 | 2011 | 289 | 0.120 |
Why?
|
| Fluorine Radioisotopes | 1 | 2018 | 425 | 0.120 |
Why?
|
| Liver Neoplasms | 6 | 2012 | 4362 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 2048 | 0.120 |
Why?
|
| Phenylthiohydantoin | 4 | 2019 | 208 | 0.120 |
Why?
|
| Adenoma | 5 | 2006 | 2163 | 0.120 |
Why?
|
| Cell Hypoxia | 2 | 2015 | 661 | 0.120 |
Why?
|
| Receptor, Insulin | 1 | 2018 | 838 | 0.120 |
Why?
|
| Estrogen Receptor beta | 2 | 2009 | 172 | 0.120 |
Why?
|
| Proteins | 4 | 2011 | 6008 | 0.120 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2016 | 318 | 0.120 |
Why?
|
| Ribonucleoproteins | 1 | 2017 | 360 | 0.120 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 6657 | 0.120 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2014 | 99 | 0.120 |
Why?
|
| Antigens, Polyomavirus Transforming | 3 | 2011 | 257 | 0.120 |
Why?
|
| Elafin | 1 | 2014 | 31 | 0.120 |
Why?
|
| Paired Box Transcription Factors | 2 | 2014 | 206 | 0.120 |
Why?
|
| Platinum | 1 | 2015 | 222 | 0.120 |
Why?
|
| Sensitivity and Specificity | 10 | 2020 | 14728 | 0.120 |
Why?
|
| Genome-Wide Association Study | 5 | 2023 | 12774 | 0.120 |
Why?
|
| Ubiquitins | 3 | 2001 | 367 | 0.120 |
Why?
|
| Cyclooxygenase 2 | 3 | 2006 | 599 | 0.120 |
Why?
|
| Phosphoric Monoester Hydrolases | 3 | 2001 | 413 | 0.120 |
Why?
|
| Proportional Hazards Models | 13 | 2020 | 12561 | 0.120 |
Why?
|
| Keratins | 3 | 2003 | 502 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2007 | 526 | 0.110 |
Why?
|
| Cell Line, Transformed | 4 | 2009 | 868 | 0.110 |
Why?
|
| Eye Proteins | 2 | 2014 | 633 | 0.110 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2009 | 480 | 0.110 |
Why?
|
| Melanocytes | 3 | 2014 | 512 | 0.110 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2015 | 264 | 0.110 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2014 | 44 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 6537 | 0.110 |
Why?
|
| DNA Repair | 3 | 2020 | 2051 | 0.110 |
Why?
|
| Cell Line | 12 | 2022 | 15609 | 0.110 |
Why?
|
| Histone Code | 1 | 2014 | 160 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2009 | 381 | 0.110 |
Why?
|
| Leuprolide | 4 | 2017 | 313 | 0.110 |
Why?
|
| Zirconium | 1 | 2014 | 110 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2016 | 624 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 109 | 0.110 |
Why?
|
| Phenotype | 23 | 2012 | 16712 | 0.110 |
Why?
|
| RNA Interference | 5 | 2021 | 2832 | 0.110 |
Why?
|
| Protein Stability | 2 | 2012 | 584 | 0.110 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2014 | 205 | 0.110 |
Why?
|
| Repressor Proteins | 2 | 2014 | 2987 | 0.110 |
Why?
|
| Pathology | 2 | 2024 | 270 | 0.110 |
Why?
|
| Ubiquitination | 3 | 2012 | 1010 | 0.110 |
Why?
|
| Benzamides | 6 | 2019 | 1381 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 12 | 2019 | 5803 | 0.110 |
Why?
|
| Rats | 15 | 2013 | 23839 | 0.110 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2014 | 112 | 0.110 |
Why?
|
| ras Proteins | 9 | 2009 | 1058 | 0.110 |
Why?
|
| Cerebellar Neoplasms | 3 | 1993 | 590 | 0.110 |
Why?
|
| Receptors, Calcitriol | 2 | 2016 | 361 | 0.110 |
Why?
|
| Serpins | 1 | 2014 | 247 | 0.110 |
Why?
|
| Parathyroid Neoplasms | 1 | 1994 | 244 | 0.110 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2011 | 103 | 0.110 |
Why?
|
| Endonucleases | 1 | 2015 | 371 | 0.110 |
Why?
|
| Selenoprotein P | 1 | 2012 | 33 | 0.110 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1998 | 712 | 0.100 |
Why?
|
| Germ-Line Mutation | 4 | 2023 | 1884 | 0.100 |
Why?
|
| Proliferating Cell Nuclear Antigen | 4 | 2005 | 287 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 8051 | 0.100 |
Why?
|
| Epidermal Growth Factor | 5 | 2008 | 699 | 0.100 |
Why?
|
| Radioisotopes | 1 | 2014 | 516 | 0.100 |
Why?
|
| Disease Models, Animal | 10 | 2014 | 18388 | 0.100 |
Why?
|
| Alleles | 7 | 2012 | 6890 | 0.100 |
Why?
|
| Cell Survival | 6 | 2022 | 5801 | 0.100 |
Why?
|
| DNA Helicases | 2 | 2015 | 853 | 0.100 |
Why?
|
| Mitosis | 3 | 2014 | 1191 | 0.100 |
Why?
|
| Nerve Growth Factors | 2 | 2014 | 566 | 0.100 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2014 | 258 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2009 | 4083 | 0.100 |
Why?
|
| Peptides | 2 | 2004 | 4368 | 0.100 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 190 | 0.100 |
Why?
|
| Cyclin A1 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Parathyroid Glands | 1 | 1994 | 522 | 0.100 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2012 | 61 | 0.100 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 111 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 11 | 2024 | 22365 | 0.100 |
Why?
|
| Membrane Glycoproteins | 6 | 2005 | 3713 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 427 | 0.100 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 146 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2012 | 93 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1999 | 1376 | 0.100 |
Why?
|
| Single-Cell Analysis | 2 | 2020 | 2531 | 0.100 |
Why?
|
| Molecular Sequence Data | 15 | 2014 | 17647 | 0.100 |
Why?
|
| Oxygen | 1 | 2004 | 4269 | 0.100 |
Why?
|
| Histocytochemistry | 2 | 2005 | 699 | 0.100 |
Why?
|
| Protein Kinases | 5 | 2009 | 1608 | 0.100 |
Why?
|
| Oligonucleotides | 2 | 2021 | 564 | 0.100 |
Why?
|
| Case-Control Studies | 12 | 2021 | 22293 | 0.100 |
Why?
|
| Pyrophosphatases | 1 | 2012 | 143 | 0.100 |
Why?
|
| Survival Analysis | 11 | 2018 | 10125 | 0.100 |
Why?
|
| Receptors, Progesterone | 3 | 2011 | 1145 | 0.100 |
Why?
|
| Precipitin Tests | 3 | 2001 | 816 | 0.100 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 1839 | 0.100 |
Why?
|
| Risk Factors | 18 | 2023 | 74915 | 0.100 |
Why?
|
| Protein Methyltransferases | 1 | 2011 | 54 | 0.090 |
Why?
|
| Eukaryotic Initiation Factors | 2 | 2008 | 83 | 0.090 |
Why?
|
| Nitriles | 4 | 2019 | 984 | 0.090 |
Why?
|
| Epigenesis, Genetic | 4 | 2017 | 3826 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2017 | 433 | 0.090 |
Why?
|
| Bromodeoxyuridine | 2 | 2009 | 310 | 0.090 |
Why?
|
| Cell Adhesion | 6 | 2020 | 3103 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2023 | 639 | 0.090 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2010 | 24 | 0.090 |
Why?
|
| Teratoma | 1 | 1994 | 405 | 0.090 |
Why?
|
| Viral Load | 1 | 2020 | 3399 | 0.090 |
Why?
|
| Kidney Neoplasms | 4 | 2011 | 4298 | 0.090 |
Why?
|
| Protein Binding | 9 | 2020 | 9376 | 0.090 |
Why?
|
| Hormones | 1 | 2015 | 870 | 0.090 |
Why?
|
| Retrospective Studies | 16 | 2023 | 81834 | 0.090 |
Why?
|
| Nurses | 1 | 2020 | 2494 | 0.090 |
Why?
|
| Cadherins | 3 | 2015 | 906 | 0.090 |
Why?
|
| Genomics | 6 | 2023 | 5909 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2014 | 9066 | 0.090 |
Why?
|
| Oligonucleotide Probes | 3 | 2007 | 417 | 0.090 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 835 | 0.090 |
Why?
|
| Hepatitis B | 1 | 1996 | 707 | 0.090 |
Why?
|
| DNA, Complementary | 5 | 2007 | 1992 | 0.090 |
Why?
|
| Pyrimidines | 4 | 2014 | 3050 | 0.090 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2010 | 60 | 0.090 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 224 | 0.090 |
Why?
|
| Pandemics | 8 | 2021 | 8753 | 0.090 |
Why?
|
| Hospitalization | 2 | 2020 | 10845 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 617 | 0.090 |
Why?
|
| Immunomagnetic Separation | 1 | 2010 | 79 | 0.090 |
Why?
|
| Progesterone | 1 | 2014 | 750 | 0.090 |
Why?
|
| Polyomavirus | 1 | 2011 | 236 | 0.090 |
Why?
|
| Glioblastoma | 2 | 2008 | 3523 | 0.090 |
Why?
|
| Sulfonamides | 2 | 2014 | 1988 | 0.090 |
Why?
|
| Thyroid Neoplasms | 3 | 2009 | 2360 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2020 | 1926 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 2040 | 0.080 |
Why?
|
| Chromogenic Compounds | 1 | 2009 | 30 | 0.080 |
Why?
|
| Genes, erbB-2 | 1 | 2010 | 162 | 0.080 |
Why?
|
| Selenium | 1 | 2012 | 419 | 0.080 |
Why?
|
| Adiponectin | 2 | 2015 | 1118 | 0.080 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 195 | 0.080 |
Why?
|
| Dissection | 2 | 2002 | 299 | 0.080 |
Why?
|
| Angiomyolipoma | 1 | 2011 | 188 | 0.080 |
Why?
|
| Longevity | 1 | 2017 | 1077 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2009 | 66 | 0.080 |
Why?
|
| Industry | 1 | 2011 | 366 | 0.080 |
Why?
|
| Exercise | 2 | 2021 | 5940 | 0.080 |
Why?
|
| Gene Fusion | 1 | 2012 | 356 | 0.080 |
Why?
|
| Mucous Membrane | 2 | 2004 | 660 | 0.080 |
Why?
|
| Ribonuclease III | 2 | 2008 | 270 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1628 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 228 | 0.080 |
Why?
|
| Hepatic Encephalopathy | 2 | 1995 | 144 | 0.080 |
Why?
|
| Tissue Culture Techniques | 1 | 2010 | 290 | 0.080 |
Why?
|
| Cell Shape | 1 | 2010 | 371 | 0.080 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2009 | 112 | 0.080 |
Why?
|
| Flow Cytometry | 6 | 2009 | 5904 | 0.080 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2007 | 440 | 0.080 |
Why?
|
| Hepatitis C | 2 | 1996 | 1594 | 0.080 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 344 | 0.080 |
Why?
|
| Models, Biological | 10 | 2018 | 9505 | 0.080 |
Why?
|
| Genetic Loci | 3 | 2015 | 2630 | 0.080 |
Why?
|
| Cells, Cultured | 10 | 2020 | 19041 | 0.080 |
Why?
|
| Transplantation, Heterologous | 4 | 2009 | 2393 | 0.080 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 3212 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 2742 | 0.080 |
Why?
|
| Jurkat Cells | 2 | 2001 | 743 | 0.080 |
Why?
|
| Computational Biology | 3 | 2015 | 3546 | 0.080 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2011 | 542 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2010 | 229 | 0.080 |
Why?
|
| Lymph Nodes | 3 | 2018 | 3472 | 0.080 |
Why?
|
| Genome, Human | 4 | 2014 | 4453 | 0.080 |
Why?
|
| Glutathione | 2 | 2013 | 587 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2279 | 0.080 |
Why?
|
| Molecular Imaging | 1 | 2015 | 825 | 0.080 |
Why?
|
| New York City | 2 | 2021 | 738 | 0.080 |
Why?
|
| Genes, DCC | 2 | 1998 | 10 | 0.080 |
Why?
|
| Neuroglia | 1 | 1994 | 961 | 0.080 |
Why?
|
| Urinary Bladder | 2 | 2012 | 1160 | 0.080 |
Why?
|
| Breast Neoplasms, Male | 2 | 2003 | 212 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2022 | 3665 | 0.070 |
Why?
|
| Liver Transplantation | 2 | 2000 | 2399 | 0.070 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2002 | 388 | 0.070 |
Why?
|
| Microarray Analysis | 2 | 2007 | 752 | 0.070 |
Why?
|
| Myofibroma | 1 | 2008 | 45 | 0.070 |
Why?
|
| RecQ Helicases | 1 | 2007 | 53 | 0.070 |
Why?
|
| Thymosin | 2 | 1998 | 47 | 0.070 |
Why?
|
| Cytoskeletal Proteins | 3 | 2003 | 1337 | 0.070 |
Why?
|
| Castration | 3 | 2012 | 150 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2009 | 621 | 0.070 |
Why?
|
| Breast | 2 | 2010 | 1976 | 0.070 |
Why?
|
| Telomerase | 4 | 2009 | 751 | 0.070 |
Why?
|
| Insulin | 5 | 2018 | 6606 | 0.070 |
Why?
|
| Nasopharynx | 2 | 2020 | 420 | 0.070 |
Why?
|
| Virulence Factors | 1 | 2011 | 512 | 0.070 |
Why?
|
| Introns | 1 | 2010 | 970 | 0.070 |
Why?
|
| Urothelium | 2 | 2008 | 275 | 0.070 |
Why?
|
| Algorithms | 2 | 2020 | 14158 | 0.070 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 575 | 0.070 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2008 | 80 | 0.070 |
Why?
|
| Tumor Suppressor Protein p14ARF | 2 | 2009 | 84 | 0.070 |
Why?
|
| Blood Proteins | 2 | 2020 | 1183 | 0.070 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 205 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 582 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2024 | 453 | 0.070 |
Why?
|
| Genetic Variation | 4 | 2015 | 6610 | 0.070 |
Why?
|
| Biotechnology | 1 | 2008 | 282 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2017 | 2589 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2021 | 1608 | 0.070 |
Why?
|
| Aspirin | 1 | 2018 | 3139 | 0.070 |
Why?
|
| Genotype | 8 | 2017 | 13047 | 0.070 |
Why?
|
| Mutation, Missense | 3 | 2014 | 2594 | 0.070 |
Why?
|
| Piperazines | 3 | 2006 | 2546 | 0.070 |
Why?
|
| Treatment Outcome | 15 | 2019 | 65409 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 5 | 2014 | 9263 | 0.070 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 435 | 0.070 |
Why?
|
| Exodeoxyribonucleases | 1 | 2007 | 191 | 0.070 |
Why?
|
| Diagnosis, Differential | 6 | 2018 | 13026 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 697 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2015 | 906 | 0.070 |
Why?
|
| Thrombosis | 1 | 2020 | 2956 | 0.070 |
Why?
|
| Lactones | 1 | 2008 | 316 | 0.070 |
Why?
|
| Biopsy, Needle | 2 | 2004 | 1629 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2010 | 755 | 0.070 |
Why?
|
| Odds Ratio | 5 | 2017 | 9687 | 0.070 |
Why?
|
| Colony-Forming Units Assay | 1 | 2006 | 352 | 0.070 |
Why?
|
| Intestinal Polyps | 2 | 2005 | 105 | 0.070 |
Why?
|
| Sirolimus | 3 | 2009 | 1542 | 0.070 |
Why?
|
| Amino Acids | 4 | 1985 | 1714 | 0.070 |
Why?
|
| Sulfites | 1 | 2006 | 83 | 0.070 |
Why?
|
| Carcinoma, Papillary | 2 | 2009 | 792 | 0.070 |
Why?
|
| Point Mutation | 3 | 2015 | 1596 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2009 | 706 | 0.060 |
Why?
|
| Fibroblasts | 4 | 2009 | 4180 | 0.060 |
Why?
|
| Cluster Analysis | 4 | 2015 | 2731 | 0.060 |
Why?
|
| United States | 12 | 2024 | 73121 | 0.060 |
Why?
|
| Antigens, Neoplasm | 5 | 2003 | 2003 | 0.060 |
Why?
|
| Disease-Free Survival | 7 | 2014 | 6856 | 0.060 |
Why?
|
| Lasers | 3 | 2008 | 952 | 0.060 |
Why?
|
| S Phase | 4 | 2000 | 425 | 0.060 |
Why?
|
| Receptors, Erythropoietin | 1 | 2006 | 144 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2010 | 1889 | 0.060 |
Why?
|
| Incidence | 7 | 2019 | 21552 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 679 | 0.060 |
Why?
|
| Gene Deletion | 5 | 2015 | 2674 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2006 | 118 | 0.060 |
Why?
|
| Biology | 1 | 2007 | 291 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 306 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 2731 | 0.060 |
Why?
|
| ROC Curve | 3 | 2020 | 3624 | 0.060 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2006 | 82 | 0.060 |
Why?
|
| Feeding Behavior | 2 | 2016 | 3202 | 0.060 |
Why?
|
| Glucose Transporter Type 1 | 2 | 2009 | 186 | 0.060 |
Why?
|
| Liver | 8 | 2008 | 7575 | 0.060 |
Why?
|
| STAT5 Transcription Factor | 1 | 2006 | 268 | 0.060 |
Why?
|
| Career Choice | 1 | 2011 | 769 | 0.060 |
Why?
|
| Cell Membrane | 3 | 2012 | 3664 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2012 | 2206 | 0.060 |
Why?
|
| Caveolins | 1 | 2005 | 102 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 3783 | 0.060 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1999 | 2444 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 2 | 2003 | 283 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 1996 | 478 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 5192 | 0.060 |
Why?
|
| Physicians | 2 | 2020 | 4615 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2006 | 276 | 0.060 |
Why?
|
| New York | 2 | 2020 | 882 | 0.060 |
Why?
|
| Tissue Engineering | 1 | 2015 | 1890 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3253 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 1494 | 0.060 |
Why?
|
| Hypoparathyroidism | 1 | 2006 | 136 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 4 | 2014 | 5442 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2000 | 2331 | 0.060 |
Why?
|
| Mucins | 1 | 2007 | 570 | 0.060 |
Why?
|
| Cycloheximide | 2 | 2021 | 343 | 0.060 |
Why?
|
| DiGeorge Syndrome | 1 | 2006 | 187 | 0.060 |
Why?
|
| Ligases | 2 | 2002 | 333 | 0.060 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2024 | 30 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 9 | 2007 | 2910 | 0.060 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2006 | 167 | 0.060 |
Why?
|
| Blotting, Southern | 4 | 2004 | 777 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2021 | 4642 | 0.060 |
Why?
|
| Reproducibility of Results | 8 | 2020 | 20231 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2011 | 3197 | 0.060 |
Why?
|
| Proteomics | 4 | 2023 | 3901 | 0.060 |
Why?
|
| Racemases and Epimerases | 1 | 2004 | 114 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2009 | 3550 | 0.060 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2005 | 199 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1998 | 338 | 0.060 |
Why?
|
| Fungal Proteins | 2 | 1999 | 908 | 0.060 |
Why?
|
| Serine | 2 | 2024 | 831 | 0.060 |
Why?
|
| GPI-Linked Proteins | 4 | 2015 | 473 | 0.060 |
Why?
|
| Mucin-1 | 2 | 2003 | 538 | 0.060 |
Why?
|
| Necrosis | 2 | 2006 | 1621 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2020 | 1765 | 0.050 |
Why?
|
| Time Factors | 14 | 2013 | 40271 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2000 | 185 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2014 | 1755 | 0.050 |
Why?
|
| Neuropilin-2 | 1 | 2023 | 55 | 0.050 |
Why?
|
| Estrogens | 1 | 2010 | 1531 | 0.050 |
Why?
|
| Morpholines | 3 | 2014 | 583 | 0.050 |
Why?
|
| Sarcoma | 1 | 2014 | 1806 | 0.050 |
Why?
|
| Gene Transfer Techniques | 3 | 2004 | 1209 | 0.050 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2003 | 136 | 0.050 |
Why?
|
| Tuberous Sclerosis | 1 | 2011 | 1040 | 0.050 |
Why?
|
| Biological Assay | 2 | 2020 | 629 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 2834 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 2007 | 1770 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 318 | 0.050 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 525 | 0.050 |
Why?
|
| Lactates | 1 | 2023 | 401 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2003 | 156 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 1143 | 0.050 |
Why?
|
| Anemia, Refractory | 1 | 2002 | 17 | 0.050 |
Why?
|
| Cyclin E | 1 | 2003 | 156 | 0.050 |
Why?
|
| Lipolysis | 1 | 2024 | 211 | 0.050 |
Why?
|
| Kallikreins | 1 | 2004 | 221 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2005 | 594 | 0.050 |
Why?
|
| Neuregulin-1 | 1 | 2003 | 136 | 0.050 |
Why?
|
| Chromosome Aberrations | 3 | 2019 | 1781 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 1104 | 0.050 |
Why?
|
| Antibodies | 2 | 2001 | 2425 | 0.050 |
Why?
|
| Langerhans Cells | 1 | 2003 | 169 | 0.050 |
Why?
|
| Adenoma, Liver Cell | 1 | 2002 | 32 | 0.050 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2002 | 61 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2005 | 423 | 0.050 |
Why?
|
| Adipocytes | 1 | 2009 | 1199 | 0.050 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 6527 | 0.050 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2011 | 1398 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2010 | 2003 | 0.050 |
Why?
|
| Blotting, Northern | 3 | 2002 | 1553 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2003 | 288 | 0.050 |
Why?
|
| Chromatography, Liquid | 2 | 2017 | 998 | 0.050 |
Why?
|
| Amino Acid Motifs | 2 | 2001 | 930 | 0.050 |
Why?
|
| Transgenes | 4 | 2008 | 1015 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2023 | 314 | 0.050 |
Why?
|
| Lipase | 1 | 2024 | 321 | 0.050 |
Why?
|
| Azacitidine | 1 | 2003 | 336 | 0.050 |
Why?
|
| Biomedical Research | 3 | 2024 | 3463 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2005 | 589 | 0.050 |
Why?
|
| Logistic Models | 4 | 2018 | 13324 | 0.050 |
Why?
|
| Inflammation | 2 | 2019 | 10865 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 243 | 0.050 |
Why?
|
| Credentialing | 1 | 2022 | 114 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2001 | 387 | 0.050 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 998 | 0.050 |
Why?
|
| Tarsal Bones | 1 | 2002 | 72 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2005 | 648 | 0.050 |
Why?
|
| Cystadenoma, Serous | 1 | 2002 | 100 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2006 | 719 | 0.050 |
Why?
|
| Mass Screening | 1 | 1997 | 5455 | 0.050 |
Why?
|
| Databases, Factual | 3 | 2014 | 8081 | 0.050 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2003 | 171 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2009 | 1706 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2001 | 114 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2022 | 300 | 0.050 |
Why?
|
| Spliceosomes | 1 | 2021 | 117 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2008 | 1539 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2005 | 489 | 0.050 |
Why?
|
| Hyperplasia | 3 | 2008 | 1154 | 0.050 |
Why?
|
| Flutamide | 1 | 2001 | 95 | 0.050 |
Why?
|
| Cyclins | 1 | 2003 | 606 | 0.050 |
Why?
|
| Recurrence | 4 | 2010 | 8510 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2015 | 876 | 0.050 |
Why?
|
| Foot Diseases | 1 | 2002 | 148 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2015 | 856 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2015 | 1640 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2014 | 6429 | 0.040 |
Why?
|
| Pyruvate Kinase | 1 | 2022 | 190 | 0.040 |
Why?
|
| Transcriptional Activation | 4 | 2010 | 1751 | 0.040 |
Why?
|
| Rats, Inbred Strains | 2 | 1996 | 2087 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 7956 | 0.040 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2021 | 147 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2014 | 640 | 0.040 |
Why?
|
| Ploidies | 2 | 1998 | 287 | 0.040 |
Why?
|
| Heterozygote | 4 | 2011 | 2792 | 0.040 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2002 | 353 | 0.040 |
Why?
|
| Convalescence | 1 | 2020 | 109 | 0.040 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 1999 | 648 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 655 | 0.040 |
Why?
|
| Phthalazines | 1 | 2022 | 396 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2020 | 277 | 0.040 |
Why?
|
| Observer Variation | 2 | 2017 | 2622 | 0.040 |
Why?
|
| Calcitonin | 1 | 2001 | 329 | 0.040 |
Why?
|
| Aminopyridines | 2 | 2014 | 578 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 507 | 0.040 |
Why?
|
| Oxidants | 2 | 2013 | 169 | 0.040 |
Why?
|
| Peptide Synthases | 1 | 2000 | 81 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 2000 | 183 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4861 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 292 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 10273 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 2003 | 0.040 |
Why?
|
| Receptors, Prolactin | 1 | 1999 | 16 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2008 | 928 | 0.040 |
Why?
|
| Cell Count | 1 | 2003 | 1835 | 0.040 |
Why?
|
| Motor Activity | 1 | 2009 | 2722 | 0.040 |
Why?
|
| Exudates and Transudates | 1 | 1999 | 175 | 0.040 |
Why?
|
| Pseudolymphoma | 1 | 1999 | 30 | 0.040 |
Why?
|
| Immunity | 2 | 2022 | 1002 | 0.040 |
Why?
|
| Mouth Neoplasms | 1 | 2004 | 598 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2003 | 1133 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 206 | 0.040 |
Why?
|
| Organ Culture Techniques | 1 | 2021 | 796 | 0.040 |
Why?
|
| Quinazolines | 3 | 2014 | 1376 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2010 | 2901 | 0.040 |
Why?
|
| Steroid 16-alpha-Hydroxylase | 1 | 2018 | 12 | 0.040 |
Why?
|
| Protein Biosynthesis | 3 | 1985 | 2096 | 0.040 |
Why?
|
| Cytokines | 3 | 2020 | 7449 | 0.040 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 15460 | 0.040 |
Why?
|
| RNA | 3 | 2003 | 2727 | 0.040 |
Why?
|
| Risk | 3 | 2016 | 9642 | 0.040 |
Why?
|
| Dependovirus | 1 | 2004 | 720 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2000 | 430 | 0.040 |
Why?
|
| Autophagy | 2 | 2021 | 1349 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2021 | 1421 | 0.040 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1999 | 240 | 0.040 |
Why?
|
| Risk Assessment | 6 | 2019 | 24311 | 0.040 |
Why?
|
| Benzimidazoles | 2 | 2014 | 864 | 0.040 |
Why?
|
| RNA Probes | 1 | 1998 | 111 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 641 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2001 | 423 | 0.040 |
Why?
|
| Neoplastic Processes | 1 | 1998 | 36 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2015 | 3615 | 0.040 |
Why?
|
| Sputum | 1 | 2020 | 511 | 0.040 |
Why?
|
| South Africa | 1 | 2023 | 1870 | 0.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2003 | 495 | 0.040 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1998 | 111 | 0.040 |
Why?
|
| Cell Communication | 2 | 2020 | 1662 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2023 | 1531 | 0.040 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2002 | 373 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2020 | 396 | 0.040 |
Why?
|
| Lead | 1 | 2023 | 880 | 0.040 |
Why?
|
| Software | 2 | 2012 | 4463 | 0.040 |
Why?
|
| Rhabdoid Tumor | 1 | 2000 | 210 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2000 | 462 | 0.040 |
Why?
|
| Diet | 1 | 2016 | 8098 | 0.040 |
Why?
|
| Smoking | 3 | 2010 | 9099 | 0.040 |
Why?
|
| Sucrase-Isomaltase Complex | 1 | 1997 | 12 | 0.040 |
Why?
|
| Liver Function Tests | 2 | 1996 | 527 | 0.040 |
Why?
|
| Catenins | 2 | 2007 | 44 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2017 | 12450 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 1984 | 1882 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2000 | 607 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 2 | 2020 | 1625 | 0.040 |
Why?
|
| Biological Transport | 2 | 2018 | 2089 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1998 | 527 | 0.040 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 2 | 2007 | 57 | 0.040 |
Why?
|
| Peroxidase | 1 | 2020 | 610 | 0.040 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2018 | 246 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2021 | 673 | 0.030 |
Why?
|
| Schizosaccharomyces | 1 | 1999 | 237 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 4780 | 0.030 |
Why?
|
| Laboratories | 1 | 2020 | 463 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2004 | 959 | 0.030 |
Why?
|
| Liver Cirrhosis | 2 | 1984 | 1950 | 0.030 |
Why?
|
| Microdissection | 2 | 2008 | 151 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2017 | 406 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1869 | 0.030 |
Why?
|
| Immunoassay | 1 | 2020 | 746 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 783 | 0.030 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2017 | 96 | 0.030 |
Why?
|
| Polyploidy | 1 | 2017 | 120 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2021 | 1094 | 0.030 |
Why?
|
| Oligo-1,6-Glucosidase | 1 | 1995 | 7 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2019 | 812 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 3 | 2014 | 2640 | 0.030 |
Why?
|
| Glucose | 1 | 2008 | 4355 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2001 | 419 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 736 | 0.030 |
Why?
|
| Reference Values | 2 | 2000 | 4941 | 0.030 |
Why?
|
| Lymphoma, T-Cell | 1 | 1999 | 304 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 1044 | 0.030 |
Why?
|
| Sucrase | 1 | 1995 | 51 | 0.030 |
Why?
|
| Clone Cells | 1 | 1999 | 1672 | 0.030 |
Why?
|
| Silver Staining | 1 | 1995 | 63 | 0.030 |
Why?
|
| Cloning, Molecular | 5 | 2002 | 4175 | 0.030 |
Why?
|
| Mice, Mutant Strains | 3 | 2005 | 1755 | 0.030 |
Why?
|
| Cholecalciferol | 1 | 2001 | 557 | 0.030 |
Why?
|
| Methyltransferases | 2 | 2012 | 375 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2015 | 1166 | 0.030 |
Why?
|
| Nevus, Pigmented | 1 | 2018 | 225 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2020 | 724 | 0.030 |
Why?
|
| Estradiol | 2 | 2016 | 1949 | 0.030 |
Why?
|
| Kinetics | 2 | 2001 | 6348 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1994 | 1305 | 0.030 |
Why?
|
| E2F3 Transcription Factor | 1 | 2015 | 36 | 0.030 |
Why?
|
| Automation | 1 | 1998 | 588 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2021 | 1338 | 0.030 |
Why?
|
| Hepatitis B, Chronic | 1 | 2000 | 413 | 0.030 |
Why?
|
| Spondylolisthesis | 1 | 1997 | 173 | 0.030 |
Why?
|
| Esophagoscopy | 1 | 1997 | 398 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2003 | 1737 | 0.030 |
Why?
|
| Genes | 1 | 1999 | 1824 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 439 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2017 | 286 | 0.030 |
Why?
|
| Genetic Engineering | 2 | 2013 | 936 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 191 | 0.030 |
Why?
|
| Anal Canal | 1 | 1998 | 376 | 0.030 |
Why?
|
| DNA | 2 | 2006 | 7213 | 0.030 |
Why?
|
| Subtraction Technique | 1 | 1998 | 519 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 1999 | 505 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 682 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2003 | 2131 | 0.030 |
Why?
|
| Animals, Genetically Modified | 2 | 2011 | 1563 | 0.030 |
Why?
|
| Palliative Care | 1 | 2010 | 3644 | 0.030 |
Why?
|
| Age Factors | 4 | 2015 | 18478 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 1995 | 257 | 0.030 |
Why?
|
| Ketoconazole | 1 | 2014 | 97 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2006 | 3145 | 0.030 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2014 | 35 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2014 | 71 | 0.030 |
Why?
|
| Species Specificity | 2 | 2010 | 2422 | 0.030 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2014 | 41 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2000 | 1079 | 0.030 |
Why?
|
| NIH 3T3 Cells | 2 | 2007 | 669 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 10784 | 0.030 |
Why?
|
| Colonic Polyps | 1 | 1999 | 557 | 0.030 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2014 | 30 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2001 | 1804 | 0.030 |
Why?
|
| Leucovorin | 2 | 2007 | 643 | 0.030 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2014 | 87 | 0.030 |
Why?
|
| Organoids | 1 | 2020 | 749 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2014 | 144 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 1066 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 1518 | 0.030 |
Why?
|
| Models, Theoretical | 2 | 2020 | 3590 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 2013 | 2232 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2002 | 11930 | 0.030 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2014 | 77 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2014 | 124 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2016 | 471 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 1994 | 138 | 0.030 |
Why?
|
| Multiprotein Complexes | 2 | 2011 | 1112 | 0.030 |
Why?
|
| S100 Proteins | 1 | 1994 | 217 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1998 | 1615 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2005 | 616 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2014 | 1056 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2018 | 743 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 1909 | 0.030 |
Why?
|
| Cullin Proteins | 1 | 2014 | 180 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 3612 | 0.030 |
Why?
|
| Actinin | 1 | 2014 | 165 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2006 | 247 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 257 | 0.030 |
Why?
|
| Specimen Handling | 1 | 1998 | 709 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2001 | 2565 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1994 | 767 | 0.030 |
Why?
|
| Pheochromocytoma | 2 | 2011 | 328 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 946 | 0.030 |
Why?
|
| Ganglioneuroma | 1 | 1993 | 53 | 0.030 |
Why?
|
| Androstadienes | 1 | 2014 | 348 | 0.030 |
Why?
|
| Binding Sites | 2 | 2015 | 6030 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2013 | 212 | 0.030 |
Why?
|
| Camptothecin | 2 | 2007 | 594 | 0.030 |
Why?
|
| Databases as Topic | 2 | 2006 | 475 | 0.030 |
Why?
|
| Selection Bias | 1 | 2014 | 360 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 1998 | 791 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1998 | 1081 | 0.030 |
Why?
|
| Chromosome Deletion | 2 | 2000 | 1390 | 0.030 |
Why?
|
| alpha Catenin | 1 | 2012 | 37 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2012 | 363 | 0.020 |
Why?
|
| Plant Extracts | 1 | 2016 | 499 | 0.020 |
Why?
|
| Indazoles | 1 | 2014 | 306 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2021 | 4294 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1994 | 560 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 720 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2014 | 395 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2004 | 3816 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2014 | 890 | 0.020 |
Why?
|
| Acetylation | 1 | 2014 | 1053 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 1998 | 1135 | 0.020 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2012 | 168 | 0.020 |
Why?
|
| Macrophages | 2 | 2023 | 5797 | 0.020 |
Why?
|
| Premenopause | 1 | 2016 | 1039 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 757 | 0.020 |
Why?
|
| Fatty Acid Desaturases | 1 | 2011 | 102 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2000 | 1031 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 1232 | 0.020 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2002 | 200 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 1984 | 2518 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2011 | 41 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 3790 | 0.020 |
Why?
|
| Exons | 4 | 2004 | 2392 | 0.020 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 1991 | 19 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1995 | 1468 | 0.020 |
Why?
|
| Body Height | 1 | 2017 | 1568 | 0.020 |
Why?
|
| COS Cells | 2 | 2004 | 1136 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2014 | 325 | 0.020 |
Why?
|
| Hepatic Duct, Common | 1 | 1991 | 48 | 0.020 |
Why?
|
| Plasmids | 2 | 2009 | 2269 | 0.020 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2017 | 1149 | 0.020 |
Why?
|
| Fluorouracil | 2 | 2007 | 1656 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 14766 | 0.020 |
Why?
|
| Receptors, Death Domain | 1 | 2010 | 31 | 0.020 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2010 | 46 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2015 | 6242 | 0.020 |
Why?
|
| Young Adult | 4 | 2020 | 60045 | 0.020 |
Why?
|
| Amino Acid Sequence | 6 | 2002 | 13452 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 802 | 0.020 |
Why?
|
| Myocardium | 1 | 2004 | 4788 | 0.020 |
Why?
|
| Pelvis | 1 | 2015 | 737 | 0.020 |
Why?
|
| Serotonin | 1 | 2015 | 1047 | 0.020 |
Why?
|
| Databases, Genetic | 2 | 2007 | 1750 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1991 | 127 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1409 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2002 | 305 | 0.020 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 225 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1999 | 1307 | 0.020 |
Why?
|
| Chromogranins | 1 | 1991 | 160 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1991 | 169 | 0.020 |
Why?
|
| E-Box Elements | 1 | 2009 | 20 | 0.020 |
Why?
|
| Calcium | 2 | 2020 | 5793 | 0.020 |
Why?
|
| Vimentin | 1 | 1991 | 257 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 2915 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 3 | 1985 | 363 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2013 | 935 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 1998 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2020 | 2024 | 0.020 |
Why?
|
| Genes, jun | 1 | 2009 | 69 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2009 | 20 | 0.020 |
Why?
|
| Myristic Acids | 1 | 2009 | 49 | 0.020 |
Why?
|
| Lymphoma | 1 | 1999 | 1907 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2020 | 2485 | 0.020 |
Why?
|
| Tunicamycin | 1 | 2009 | 109 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2009 | 89 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1997 | 1795 | 0.020 |
Why?
|
| Bile Ducts | 1 | 1991 | 288 | 0.020 |
Why?
|
| Child, Preschool | 5 | 2020 | 42623 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 685 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 1814 | 0.020 |
Why?
|
| Metaplasia | 1 | 2010 | 326 | 0.020 |
Why?
|
| Chronic Disease | 3 | 2017 | 9382 | 0.020 |
Why?
|
| Nevus | 1 | 2011 | 206 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 1131 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1995 | 1415 | 0.020 |
Why?
|
| Penetrance | 1 | 2011 | 384 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2021 | 3080 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1997 | 1494 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 8 | 1 | 2008 | 49 | 0.020 |
Why?
|
| Program Evaluation | 1 | 1997 | 2508 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 808 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 1991 | 458 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2022 | 8730 | 0.020 |
Why?
|
| Sicily | 1 | 2008 | 10 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 1197 | 0.020 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2009 | 199 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1999 | 3048 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2021 | 3063 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 979 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 616 | 0.020 |
Why?
|
| Tubulin | 1 | 1992 | 695 | 0.020 |
Why?
|
| Body Weight | 2 | 2017 | 4630 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 412 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2680 | 0.020 |
Why?
|
| Health Surveys | 2 | 2010 | 4056 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 1339 | 0.020 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2008 | 147 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 1997 | 1885 | 0.020 |
Why?
|
| Calcium Channels, T-Type | 1 | 2007 | 28 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 79 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 369 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5308 | 0.020 |
Why?
|
| Sweden | 1 | 2010 | 1382 | 0.020 |
Why?
|
| Quinolines | 1 | 2012 | 769 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 1999 | 1930 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 10358 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2656 | 0.020 |
Why?
|
| Cell Separation | 2 | 2004 | 1726 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 1174 | 0.020 |
Why?
|
| Fixatives | 1 | 2006 | 90 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 1744 | 0.020 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2006 | 23 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 3735 | 0.020 |
Why?
|
| Mesoderm | 1 | 2009 | 679 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 548 | 0.020 |
Why?
|
| Myristic Acid | 1 | 2005 | 49 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 1368 | 0.020 |
Why?
|
| Infant | 4 | 2020 | 36497 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2008 | 539 | 0.020 |
Why?
|
| Overweight | 1 | 2017 | 2428 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2015 | 2170 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2008 | 428 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2007 | 268 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2006 | 83 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1973 | 0.020 |
Why?
|
| Geography | 1 | 2008 | 654 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2006 | 151 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 848 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2009 | 1343 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2150 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 1660 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 727 | 0.020 |
Why?
|
| Carcinoma, Medullary | 1 | 2005 | 116 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2006 | 314 | 0.020 |
Why?
|
| Lymphocytes | 2 | 2006 | 2611 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 2012 | 4249 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2008 | 639 | 0.020 |
Why?
|
| Immunoelectrophoresis | 1 | 1984 | 94 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2012 | 1247 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 399 | 0.010 |
Why?
|
| Feedback, Physiological | 1 | 2007 | 480 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2009 | 1497 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 635 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1993 | 1265 | 0.010 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2009 | 633 | 0.010 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2005 | 237 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 3111 | 0.010 |
Why?
|
| Octopamine | 1 | 1984 | 43 | 0.010 |
Why?
|
| MyoD Protein | 1 | 2004 | 141 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2008 | 579 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2004 | 266 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 3230 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2012 | 2127 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2005 | 619 | 0.010 |
Why?
|
| Lac Operon | 1 | 2004 | 237 | 0.010 |
Why?
|
| Age of Onset | 1 | 2011 | 3342 | 0.010 |
Why?
|
| gamma Catenin | 1 | 2003 | 45 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2004 | 248 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 1337 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2004 | 753 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 1674 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2004 | 209 | 0.010 |
Why?
|
| Desmoplakins | 1 | 2003 | 63 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2005 | 2173 | 0.010 |
Why?
|
| Cyclin D2 | 1 | 2003 | 98 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 2009 | 4572 | 0.010 |
Why?
|
| Genes, MDR | 1 | 2003 | 36 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2003 | 122 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2006 | 424 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 3207 | 0.010 |
Why?
|
| Amides | 1 | 2005 | 452 | 0.010 |
Why?
|
| Ammonia | 1 | 1984 | 249 | 0.010 |
Why?
|
| Chemokine CCL20 | 1 | 2003 | 64 | 0.010 |
Why?
|
| Child | 4 | 2020 | 80863 | 0.010 |
Why?
|
| Wounds, Penetrating | 1 | 1985 | 316 | 0.010 |
Why?
|
| Receptors, CCR7 | 1 | 2003 | 106 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1985 | 313 | 0.010 |
Why?
|
| Receptors, CCR6 | 1 | 2003 | 74 | 0.010 |
Why?
|
| Cystectomy | 1 | 2007 | 644 | 0.010 |
Why?
|
| Body Fluids | 1 | 2004 | 322 | 0.010 |
Why?
|
| Rabbits | 1 | 2009 | 4786 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5367 | 0.010 |
Why?
|
| Complement C3 | 1 | 1984 | 434 | 0.010 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2003 | 105 | 0.010 |
Why?
|
| Phenylalanine | 1 | 1984 | 366 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 742 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2007 | 946 | 0.010 |
Why?
|
| Protein Transport | 1 | 2008 | 1963 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2020 | 26395 | 0.010 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 2002 | 53 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2012 | 3442 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2004 | 564 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 715 | 0.010 |
Why?
|
| Massachusetts | 2 | 2007 | 8908 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2004 | 411 | 0.010 |
Why?
|
| Chemokines, CC | 1 | 2003 | 286 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 467 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 432 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 2004 | 634 | 0.010 |
Why?
|
| Health Personnel | 1 | 2015 | 3384 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2002 | 135 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 426 | 0.010 |
Why?
|
| Codon | 2 | 1995 | 599 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 1885 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 792 | 0.010 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 1984 | 269 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2003 | 342 | 0.010 |
Why?
|
| Thiazoles | 1 | 2008 | 1541 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 2002 | 438 | 0.010 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2002 | 152 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1984 | 807 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 522 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2004 | 877 | 0.010 |
Why?
|
| Adolescent | 4 | 2020 | 89168 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2005 | 873 | 0.010 |
Why?
|
| Genes, abl | 1 | 2000 | 69 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 148 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1984 | 892 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2013 | 3955 | 0.010 |
Why?
|
| Genetic Testing | 2 | 2007 | 3586 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 190 | 0.010 |
Why?
|
| Temperature | 1 | 2007 | 2237 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1984 | 1251 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2003 | 482 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 2000 | 4622 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 862 | 0.010 |
Why?
|
| Esophagostomy | 1 | 2000 | 6 | 0.010 |
Why?
|
| Dimethylnitrosamine | 1 | 2000 | 17 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 750 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2010 | 3234 | 0.010 |
Why?
|
| Leishmania major | 1 | 2000 | 60 | 0.010 |
Why?
|
| Oxidoreductases | 1 | 2002 | 412 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 383 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2003 | 601 | 0.010 |
Why?
|
| Paraffin | 1 | 1999 | 36 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2005 | 1833 | 0.010 |
Why?
|
| Retroviridae | 1 | 2002 | 850 | 0.010 |
Why?
|
| Jejunostomy | 1 | 2000 | 61 | 0.010 |
Why?
|
| Tissue Embedding | 1 | 1999 | 43 | 0.010 |
Why?
|
| Aging | 1 | 1999 | 8761 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 1668 | 0.010 |
Why?
|
| Half-Life | 1 | 2000 | 650 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2005 | 949 | 0.010 |
Why?
|
| Tyrosine | 1 | 1984 | 1428 | 0.010 |
Why?
|
| Cause of Death | 1 | 2010 | 3727 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 425 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2006 | 2604 | 0.010 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2000 | 163 | 0.010 |
Why?
|
| Genome | 1 | 2007 | 1749 | 0.010 |
Why?
|
| Endosomes | 1 | 2002 | 526 | 0.010 |
Why?
|
| Zebrafish | 1 | 2011 | 3038 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 674 | 0.010 |
Why?
|
| Pseudogenes | 1 | 1999 | 104 | 0.010 |
Why?
|
| Digestive System | 1 | 2000 | 244 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 842 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2003 | 1393 | 0.010 |
Why?
|
| Neutropenia | 1 | 2004 | 892 | 0.010 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2000 | 175 | 0.010 |
Why?
|
| Centromere | 1 | 2000 | 215 | 0.010 |
Why?
|
| DNA Probes | 1 | 2000 | 542 | 0.010 |
Why?
|
| Histones | 1 | 2009 | 2595 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 927 | 0.010 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1985 | 813 | 0.010 |
Why?
|
| Doxycycline | 1 | 2000 | 348 | 0.010 |
Why?
|
| Colon | 2 | 1998 | 1804 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1999 | 1841 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 2000 | 223 | 0.010 |
Why?
|
| Keratinocytes | 1 | 2003 | 879 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2003 | 776 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 3854 | 0.010 |
Why?
|
| Trophoblasts | 1 | 2000 | 224 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 420 | 0.010 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 1998 | 88 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 2751 | 0.010 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 1999 | 178 | 0.010 |
Why?
|
| Genes, Fungal | 1 | 1999 | 440 | 0.010 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1999 | 219 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 4417 | 0.010 |
Why?
|
| Medical Records | 1 | 2003 | 1413 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 1703 | 0.010 |
Why?
|
| Osteoblasts | 1 | 2003 | 1154 | 0.010 |
Why?
|
| Receptors, Cell Surface | 2 | 1997 | 2819 | 0.010 |
Why?
|
| Vitamin D | 1 | 2011 | 3311 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 3351 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2001 | 1891 | 0.010 |
Why?
|
| Japan | 1 | 2001 | 1418 | 0.010 |
Why?
|
| Hemodynamics | 2 | 1984 | 4202 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 368 | 0.010 |
Why?
|
| RNA, Antisense | 1 | 1996 | 136 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2004 | 1183 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 1997 | 141 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2002 | 1977 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2000 | 1158 | 0.010 |
Why?
|
| Neurons | 1 | 1995 | 9504 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 2298 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1995 | 221 | 0.010 |
Why?
|
| Testis | 1 | 1999 | 783 | 0.010 |
Why?
|
| Radioactive Tracers | 1 | 1995 | 68 | 0.010 |
Why?
|
| Arthrodesis | 1 | 1997 | 186 | 0.010 |
Why?
|
| Puberty | 1 | 1999 | 502 | 0.010 |
Why?
|
| Genes, Retinoblastoma | 1 | 1995 | 125 | 0.010 |
Why?
|
| Plasma Cells | 1 | 1999 | 598 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 3417 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1995 | 317 | 0.010 |
Why?
|
| Vaccines | 1 | 2004 | 845 | 0.010 |
Why?
|
| Galectin 3 | 1 | 1997 | 240 | 0.010 |
Why?
|
| Adenylate Cyclase Toxin | 1 | 1994 | 25 | 0.010 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 1995 | 138 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1995 | 363 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1994 | 154 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 1994 | 176 | 0.010 |
Why?
|
| Anemia | 1 | 2004 | 1521 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3974 | 0.010 |
Why?
|
| Postoperative Complications | 3 | 2009 | 15880 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1998 | 993 | 0.010 |
Why?
|
| Receptors, Thrombopoietin | 1 | 1995 | 160 | 0.010 |
Why?
|
| Molecular Biology | 1 | 1998 | 573 | 0.010 |
Why?
|
| Nipples | 1 | 1996 | 230 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1997 | 920 | 0.010 |
Why?
|
| Spleen | 1 | 2000 | 2298 | 0.010 |
Why?
|
| Pyridines | 1 | 2005 | 2888 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 1995 | 389 | 0.010 |
Why?
|
| Epitopes | 1 | 2000 | 2526 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 1998 | 12096 | 0.010 |
Why?
|
| Thrombopoietin | 1 | 1995 | 226 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 1734 | 0.010 |
Why?
|
| Safety | 1 | 1998 | 1159 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2001 | 4041 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1984 | 1937 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 8201 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1998 | 1727 | 0.010 |
Why?
|
| Somatostatin | 1 | 1994 | 448 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1998 | 1794 | 0.010 |
Why?
|
| Probability | 1 | 1998 | 2483 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1998 | 1444 | 0.010 |
Why?
|
| Remission Induction | 1 | 1998 | 2408 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1996 | 1972 | 0.010 |
Why?
|
| CHO Cells | 1 | 1994 | 1382 | 0.010 |
Why?
|
| Fetus | 1 | 1999 | 1883 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 4213 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2000 | 4834 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1993 | 354 | 0.010 |
Why?
|
| Cricetinae | 1 | 1994 | 2423 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1998 | 2925 | 0.010 |
Why?
|
| Karyotyping | 1 | 1992 | 1173 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 8373 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1995 | 736 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1995 | 1193 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 4984 | 0.010 |
Why?
|
| Actins | 1 | 1996 | 2064 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1996 | 1092 | 0.000 |
Why?
|
| Brain | 1 | 1994 | 27438 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1995 | 6241 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1995 | 2865 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1998 | 8559 | 0.000 |
Why?
|
| Lung | 1 | 2004 | 10090 | 0.000 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1984 | 46 | 0.000 |
Why?
|
| Cerebellum | 1 | 1992 | 1515 | 0.000 |
Why?
|
| Starvation | 1 | 1985 | 141 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1984 | 398 | 0.000 |
Why?
|
| Prevalence | 1 | 2001 | 15880 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1985 | 826 | 0.000 |
Why?
|
| Diagnostic Imaging | 1 | 1998 | 3543 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1995 | 3408 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1992 | 6353 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 7471 | 0.000 |
Why?
|
| Peptide Hydrolases | 1 | 1985 | 618 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 36840 | 0.000 |
Why?
|
| Triglycerides | 1 | 1985 | 2465 | 0.000 |
Why?
|
| Sepsis | 1 | 1985 | 2602 | 0.000 |
Why?
|